Table 2

Clinical and biochemical characteristics of the 129 cirrhotic patients subdivided according to six month survival

Survived patientsDeceased patientsp Value
Data are median (range).
INR, international normalised ratio; MELD, model for end stage liver disease; MELDaetiology, model for end stage liver disease computed including aetiology of liver disease; MEGX, monoethylglycinexylidide.
Sex (M/F) 86/31 9/3NS
Age (y) 49 (22–75) 55 (35–71)NS
Encephalopathy (yes/no)10/1071/11NS
Ascites (yes/no) 44/73 9/30.03
Bilirubin (mg/dl) 1.7 (0.3–12) 3.1 (1.6–6.1)0.002
Albumin (g/dl) 3.5 (2.4–5) 2.9 (2.3–4.3)0.002
Prothrombin activity (%) 58 (31–100) 50 (30–85)0.01
Child-Pugh score 7 (5–12) 10 (6–14)0.0002
Creatinine (mg/dl) 0.9 (0.6–1.3) 1.0 (0.8–1.3)NS
INR 1.6 (1.0–2.9) 1.9 (1.1–2.9)0.01
MELD score 7 (−5–17) 11 (6–19)0.0007
MELDaetiology score 12 (−5–23) 16 (13–25)0.0002
MEGX15 (ng/ml) 13.8 (0–110.8) 7.2 (0–29.7)0.03
MEGX30 (ng/ml) 20.2 (2.2–90.9) 9 (0.58–39)0.0007
MEGX60 (ng/ml) 26.1 (4.1–92.9) 14.3 (0.95–40)0.001